Blood alterations preceding clinical manifestation of glioblastoma.

被引：0
|
作者：
Ilhan-Mutlu, Aysegul
Wagner, Ludwig
Woehrer, Adelheid
Susanne, Jungwirth
Marosi, Christine
Fischer, Peter
Preusser, Matthias
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Danube Hosp, Dept Psychiat, Vienna, Austria
[3] Med Univ Vienna, Inst Neurol, Vienna, Austria
[4] Med Univ Vienna, Ctr Comprehens Canc, CNS Tumours Unit, Vienna, Austria
[5] Med Univ Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2024
引用
收藏
页数：1
相关论文
共 50 条
  • [11] AUGMENTATIVE CRANIOTOMY IN RECURRENT GLIOBLASTOMA. PRELIMINARY CLINICAL AND RADIOLOGICAL OUTCOMES
    Arcidiacono, U. A.
    Berra, L.
    Serraino, A.
    Cedrone, G.
    Venditti, E.
    Armocida, D.
    Quinzi, A.
    Brunetto, F.
    D'Angelo, L.
    Di Norcia, V
    Frati, A.
    Familiari, P.
    Santoro, A.
    NEURO-ONCOLOGY, 2022, 24
  • [12] Association of clinical phenotype and treatment history with survival in adult brainstem glioblastoma.
    Nam, Jooyeon
    Harrison, Rebecca A.
    Weathers, Shiao-Pei S.
    Pillainayagam, Clement
    De Groot, John Frederick
    Kamiya-Matsuoka, Carlos
    Loghin, Monica Elena
    Penas-Prado, Marta
    Yung, W. K. Alfred
    Li, Jing
    Ferguson, Sherise D.
    O'Brien, Barbara Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [13] Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
    Bota, D. A.
    Eroglu, Z.
    Reardon, D. A.
    Fu, B. D.
    Norfleet, J.
    Desjardins, A.
    Linskey, M. E.
    Peters, K.
    Friedman, H. S.
    Vredenburgh, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [14] Use of immunotherapy in recurrent glioblastoma.
    Sunnrall, Ashley Love
    Jennings, David Lowell
    Haggstrom, Daniel Ernest
    Symanowski, James Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [15] Genetic analysis of congenital glioblastoma.
    Castellano-Sanchez, AA
    Shehata, B
    Djalilvand, A
    Hawkins, C
    Yost, RB
    Greco, C
    Ohgaki, H
    Perry, A
    Brat, DJ
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (05): : 438 - 438
  • [16] LONG-TERM SURVIVING GLIOBLASTOMA. CLINICAL, MOLECULAR AND SURVIVAL ANALYSES
    Comas Anton, S.
    Moreno, S.
    Antelo, M.
    Carrato, C.
    Balana, C.
    Castaner, S.
    Hernandez, A.
    Hostalot, C.
    Domenech, M.
    Villa, S.
    NEURO-ONCOLOGY, 2023, 25
  • [17] Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma.
    Liu, Yang
    Richardson, Margie
    Warren, Kwanza
    Strawderman, Myla S.
    Mohile, Nimish
    Milano, Michael T.
    Walter, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] APOE genotype and outcome in glioblastoma.
    Zunarelli, E
    Rampling, R
    Murray, LS
    Stewart, J
    Nicoll, JAR
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (05): : 518 - 518
  • [19] A gene expression signature suggests molecular alterations preceding prostate tumor manifestation
    Sueltmann, H.
    Schlomm, T.
    Hellwinkel, O.
    Buness, A.
    Ruschhaupt, M.
    Erbersdobler, A.
    Luebke, A.
    Luu, V. -D.
    Huland, H.
    Poustka, A.
    ONKOLOGIE, 2008, 31 : 189 - 189
  • [20] A STUDY OF CLINICAL AND MOLECULAR PROGNOSTIC FACTORS FOR RESPONSE TO REGORAFENIB IN RECURRENT GLIOBLASTOMA.
    Chiesa, Silvia
    Mangraviti, Antonella
    Martini, Maurizio
    Cenci, Tonia
    Mazzarella, Ciro
    Gaudino, Simona
    Bracci, Serena
    Martino, Antonella
    Della Pepa, Giuseppe M.
    Offi, Martina
    Gessi, Marco
    Russo, Rosellina
    Martucci, Matia
    Bartoli, Francesco Beghella
    Di Bonaventura, Rina
    Larocca, Luigi M.
    Lauretti, Liverana
    Olivi, Alessandro
    Pallini, Roberto
    Balducci, Mario
    D'Alessandris, Quintino Giorgio
    NEURO-ONCOLOGY, 2022, 24 : 12 - 12
12345